News and Trends 21 Jun 2023 FDA clears T-Cell receptor natural killer cell therapy for sarcoma Replay, a genome writing company, and The University of Texas MD Anderson Cancer Center (MD Anderson), have announced that the U.S. Food & Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, an engineered T-cell receptor natural killer (TCR-NK) cell therapy for advanced synovial […] June 21, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Jun 2023 Five latest advancements in osteoporosis research Osteoporosis is a condition that causes bones to become extremely weak, making them more likely to break. In fact, in extremely serious cases of osteoporosis, even a cough or a minor bump can result in a fracture. Often referred to as a ‘silent disease’, many people who develop the condition will not be aware they […] June 21, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 BIO International Convention 2023: The Highlights BIO International Convention, one of the largest networking events hosted for the biotech industry, has been influential in helping biopharmas discover new opportunities and building and strengthening partnerships within the biotech and pharma community. This year, the event took place from June 5 to 8, in the bustling biotech hotspot of Boston, Massachusetts, and saw […] June 20, 2023 - 14 minutesmins - By Dylan Kissane Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 NodThera announces positive inflammatory disease data NodThera has announced positive data from first-in-human studies of its lead therapeutic candidates, NT-0249 and NT-0796. In the studies, both candidates were shown to clearly inhibit the NLRP3 inflammasome, a highly validated drug target that plays a pivotal role in controlling inflammatory diseases. The differentiated design characteristics of each candidate enabled them to penetrate different […] June 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 Lighting up cancer: FluoGuide announces positive results from head & neck cancer trial FluoGuide A/S, a Danish biotech company, has announced positive interim results from the phase IIa trial of its lead product FG001 in head & neck cancer. FG001 was shown to illuminate tumors in all of the patients. Data show all 12 patients in the first two cohorts, undergoing surgery for head & neck squamous cell […] June 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 FDA puts hold on Arcellx myeloma program following patient death Arcellx, Inc. has received notification from the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on its CART-ddBCMA investigational new drug (IND) for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). The clinical hold was received on June 16, following a recent patient death. The company said […] June 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 Anoat raises funds to tackle cystic fibrosis Anoat Therapeutics, a French preclinical stage biotechnology company specialized in cystic fibrosis (CF), has raised €2 million ($2.17 million) in seed funding from AdBio partners. Anoat will use the funds to conduct additional in vivo and in vitro pharmacology assessments and select a lead candidate. Anoat Therapeutics’ goal is to bring a transformative and mutation-agnostic […] June 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 Clearance for anti-tumor bispecific antibody trial TG ImmunoPharma Co., Ltd. (TGI), which focuses on the development of novel immuno-oncology therapies, says the FDA has granted clearance for the clinical trial of TGI-6, its bispecific antibody. TGI-6 targets unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, enabling potent anti-tumor responses. TGI said the antibody demonstrates exceptional anti-tumor activity, favorable safety profiles, and […] June 20, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jun 2023 Allgenesis says dry eye patients’ trial data ‘encouraging’ Allgenesis Biotherapeutics Inc., a clinical-stage specialty pharmaceutical company focused on developing novel ophthalmic drugs, has announced topline data from its phase 1b clinical trial for AG-80308, a first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop for the treatment of dry eye disease (DED). AG-80308 was considered safe at all doses […] June 19, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jun 2023 Trial shows colorectal cancer drug efficacy HUTCHMED (China) Limited and Takeda have announced results of their phase III FRESCO‑2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer (CRC), which were published in The Lancet. Fruquintinib is a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3. FRESCO-2 is a global phase […] June 19, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 19 Jun 2023 Gene therapy: a promising solution for sickle cell disease Sickle cell disease is debilitating, and many people who suffer with it find that their lives are defined by pain. This means a curative treatment would be completely life–altering, and, as we observe World Sickle Cell Day on June 19, we explore how gene therapy could be the most promising solution for curing sickle cell […] June 19, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 16 Jun 2023 Can ChatGPT be used to advance drug discovery? Chat GPT – which is a large language model (LLM) and belongs to a family of artificial intelligence (AI) known as generative AI – has been a revelation for many people around the world, and, since its launch, has been used by professionals in many industries to assist with work-related tasks, such as editing and […] June 16, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email